Valuation: Cogstate Limited

Market Cap 559M 389M 345M 322M 294M 554M 37.35B 3.9B 1.51B 19.09B 1.46B 1.43B 61.28B P/E 2027 *
26.1x
P/E 2028 * 20.9x
Enterprise Value 495M 344M 306M 285M 260M 490M 33.06B 3.45B 1.34B 16.9B 1.29B 1.26B 54.24B EV / Sales 2027 *
4.63x
EV / Sales 2028 * 3.89x
Free-Float
56.35%
Yield 2027 *
1.51%
Yield 2028 * 1.78%
1 day+3.31%
1 week+10.90%
Current month+3.31%
1 month+10.90%
3 months+30.00%
6 months+56.00%
Current year+46.25%
1 week 2.26
Extreme 2.265
2.34
1 month 2.26
Extreme 2.265
2.34
Current year 1.26
Extreme 1.26
2.4
1 year 1.26
Extreme 1.26
2.4
3 years 0.55
Extreme 0.553
2.4
5 years 0.55
Extreme 0.553
2.4
10 years 0.14
Extreme 0.14
2.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 17/12/1999
Chief Executive Officer - 01/12/2005
Director of Finance/CFO - 01/02/2021
Director TitleAgeSince
Director/Board Member - 01/03/2011
Chairman 67 03/11/2009
Director/Board Member - 20/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
+3.31%+10.90% - - 389M
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average +0.13%-0.59%+52.63%+128.54% 43.39B
Weighted average by Cap. +0.12%-0.84%+56.96%+138.26%

Financials

2027 *2028 *
Net sales 107M 74.34M 66.05M 61.65M 56.19M 106M 7.15B 746M 289M 3.65B 279M 273M 11.72B 123M 85.18M 75.68M 70.63M 64.38M 121M 8.19B 855M 331M 4.19B 320M 313M 13.43B
Net income 21.73M 15.1M 13.42M 12.52M 11.42M 21.53M 1.45B 152M 58.73M 742M 56.7M 55.47M 2.38B 26.88M 18.68M 16.6M 15.49M 14.12M 26.63M 1.8B 188M 72.66M 918M 70.15M 68.63M 2.95B
Net Debt -64.24M -44.65M -39.67M -37.02M -33.75M -63.65M -4.29B -448M -174M -2.19B -168M -164M -7.04B -81.78M -56.84M -50.5M -47.14M -42.96M -81.03M -5.46B -570M -221M -2.79B -213M -209M -8.96B
Logo Cogstate Limited
Cogstate Limited is a neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Its principal activities are the creation, validation, and commercialization of digital brain health assessments; and design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Administration. In the Clinical Trials segment, the technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical, and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians and/or hospitals to assess cognitive decline.
Employees
160
Date Price Change Volume
01/10/26 $2.340 +3.31% 293
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.290AUD
Average target price
4.312AUD
Spread / Average Target
+31.07%

Quarterly revenue - Rate of surprise